|
Training Grant I-2 |
Donald Kohn |
Training Grant 1 |
$2,173,872 |
|
Clinical Trial Stage Projects |
Michael Pulsipher |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) |
$4,825,587 |
|
New Faculty Physician Scientist |
Tracy Grikscheit |
The generation and expansion of tissue-engineered small intestine from human stem/ progenitor cells: a preclinical study of functional translation |
$3,146,160 |
|
Quest - Discovery Stage Research Projects |
Mark Frey |
Universal Pluripotent Liver Failure Therapy (UPLiFT) |
$1,297,512 |
|
Disease Team Planning |
Donald Kohn |
STEM CELL GENE THERAPY FOR SICKLE CELL DISEASE |
$12,131 |
|
Research Training Grant |
Ching-Ling Lien |
CIRM Training Program for Stem Cell and Regenerative Medicine Research |
$4,999,500 |
|
Comprehensive Grant |
Gay Crooks |
Regulated Expansion of Lympho-hematopoietic Stem and Progenitor Cells from Human Embryonic Stem Cells (hESC) |
$575,994 |
|
SPARK |
Mark Frey |
Stem Cell and Regenerative Medicine Summer Internships for High School Students from Under-Served Communities |
$508,750 |
|
SEED Grant |
Elizabeth Lawlor |
hESC as tools to investigate the neural crest origin of Ewing's sarcoma |
$595,576 |
|
Shared Labs |
Carolyn Lutzko |
The Childrens Hospital of Los Angeles hESC Facility |
$1,684,648 |
|
New Faculty II |
Tracy Grikscheit |
Mechanism of Tissue Engineered Small Intestine Formation |
$3,211,122 |
|
Early Translational II |
Markus Muschen |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$850,769 |
|
Shared Labs |
David Warburton |
The Childrens Hospital of Los Angeles hESC Facility |
$1,750,259 |
|
Therapeutic Translational Research Projects |
Mark Frey |
ASCENT- Advanced Stem Cell Enteric Neuropathy Therapy |
$7,077,352 |
|
Research Training II |
David Warburton |
CHLA Stem Cell Training Grant |
$5,020,920 |
|
Inception - Discovery Stage Research Projects |
Senta Georgia |
Developing a personalized approach to beta cell replacement for patients with a genetic form of diabetes |
$179,995 |
